Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development

This publication has 49 references indexed in Scilit:

• Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
  Nature Clinical Practice Cardiovascular Medicine, 2008
• Efficacy and Tolerability of Fluvastatin XL 80 mg Alone, Ezetimibe Alone, and the Combination of Fluvastatin XL 80 mg With Ezetimibe in Patients With a History of Muscle-Related Side Effects With Other Statins
  The American Journal of Cardiology, 2008
• Serum Proprotein Convertase Subtilisin Kexin Type 9 Is Correlated Directly with Serum LDL Cholesterol
  Clinical Chemistry, 2007
• The Role of Coenzyme Q10 in Statin-Associated Myopathy: A Systematic Review
  Published by Elsevier ,2007
• Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease
  New England Journal of Medicine, 2006
• Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations
  The American Journal of Cardiology, 2005
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
  Nature Genetics, 2003
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• Zaragozic Acids D and D₂: Potent Inhibitors of Squalene Synthase and of Ras Farnesyl-Protein Transferase
  Journal of Natural Products, 1993
• Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
  The Journal of Clinical Pharmacology, 1993